FTC Endorses Simplification of Biosimilar Drug Approval Process to Boost Market Competition

The Federal Trade Commission (FTC) has thrown its support behind a proposal aimed at simplifying the process for drugmakers to demonstrate that biosimilar medicines are safe alternatives to their more expensive biologic counterparts. The agency contends that this measure would foster competition in the pharmaceutical market and help alleviate consumer confusion. For further details, read the original article here.